Torrent Pharma's US business is set to benefit from new launches and stronger growth momentum, while Germany is likely to see ...

Torrent Pharmaceuticals added 1.53% to Rs 3,292.95 after the company's consolidated net profit increased 10.91% to Rs 498 crore in Q4 FY25 as against Rs 449 crore posted in Q4 FY24.

On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.

Prabhudas Lilladher recommended accumulate rating on Torrent Pharmaceuticals with a target price of Rs 3670 in its research ...

Nifty Pharma stocks, including GSK, Jubilant Pharmova, Eris Life, Gland Pharma and Torrent Pharma, saw gains up to 8% as ...

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...

Torrent Pharmaceuticals Ltd on Tuesday reported an 11 per cent rise in consolidated net profit at Rs 498 crore in the fourth ...

Torrent Pharmaceuticals reported steady growth in Q4 with an 11% rise in profit and strong margins. The board recommended a ...

Torrent Pharmaceuticals reports strong revenue growth in key markets, posting a 15.4% rise in net profit for FY 2024-25.

The drugmaker, part of the ₹45,000-crore Torrent Group, also announced a leadership transition. As part of a long-term ...

Torrent Pharmaceuticals has appointed Aman Mehta, son of current chairman Samir Mehta, as Managing Director, effective August ...